Cargando…

Monitoring of Lipids, Enzymes, and Creatine Kinase in Patients on Lipid-Lowering Drug Therapy

A number of plasma lipid parameters have been used to estimate cardiovascular risk and to be targets for treatment to reduce risk. Most risk algorithms are based on total cholesterol (T-C) or low-density lipoprotein cholesterol (LDL-C) and high-density lipoprotein cholesterol (HDL-C), and most inter...

Descripción completa

Detalles Bibliográficos
Autores principales: Wiklund, Olov, Pirazzi, Carlo, Romeo, Stefano
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2013
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3751280/
https://www.ncbi.nlm.nih.gov/pubmed/23888382
http://dx.doi.org/10.1007/s11886-013-0397-8
_version_ 1782281567038603264
author Wiklund, Olov
Pirazzi, Carlo
Romeo, Stefano
author_facet Wiklund, Olov
Pirazzi, Carlo
Romeo, Stefano
author_sort Wiklund, Olov
collection PubMed
description A number of plasma lipid parameters have been used to estimate cardiovascular risk and to be targets for treatment to reduce risk. Most risk algorithms are based on total cholesterol (T-C) or low-density lipoprotein cholesterol (LDL-C) and high-density lipoprotein cholesterol (HDL-C), and most intervention trials have targeted the LDL-C levels. Emerging measures, which in some cases may be better for risk calculation and as alternative treatment targets, are apolipoprotein B and non-HDL-C. Other lipid measures that may contribute in risk analysis are triglycerides (TG), lipoprotein(a), and lipoprotein-associated phospholipase A(2). The primary treatment target in cardiovascular prevention is LDL-C, and potential alternative targets are apoB and non-HDL-C. In selected individuals at high cardiovascular (CV) risk, TG should be targeted, but HDL-C, Lp(a), and ratios such as LDL-C/HDL-C or apoB/apoAI are not recommended as treatment targets. Lipids should be monitored during titration to targets. Thereafter, lipids should be checked at least once a year or more frequently to improve treatment adherence if indicated. Monitoring of muscle and liver enzymes should be done before the start of treatment. In stable conditions during treatment, the focus should be on clinical symptoms that may alert muscle or liver complications. Routine measurement of CK or ALT is not necessary during treatment with statins.
format Online
Article
Text
id pubmed-3751280
institution National Center for Biotechnology Information
language English
publishDate 2013
publisher Springer US
record_format MEDLINE/PubMed
spelling pubmed-37512802013-08-27 Monitoring of Lipids, Enzymes, and Creatine Kinase in Patients on Lipid-Lowering Drug Therapy Wiklund, Olov Pirazzi, Carlo Romeo, Stefano Curr Cardiol Rep Lipid Abnormalities and Cardiovascular Prevention (G De Backer, Section Editor) A number of plasma lipid parameters have been used to estimate cardiovascular risk and to be targets for treatment to reduce risk. Most risk algorithms are based on total cholesterol (T-C) or low-density lipoprotein cholesterol (LDL-C) and high-density lipoprotein cholesterol (HDL-C), and most intervention trials have targeted the LDL-C levels. Emerging measures, which in some cases may be better for risk calculation and as alternative treatment targets, are apolipoprotein B and non-HDL-C. Other lipid measures that may contribute in risk analysis are triglycerides (TG), lipoprotein(a), and lipoprotein-associated phospholipase A(2). The primary treatment target in cardiovascular prevention is LDL-C, and potential alternative targets are apoB and non-HDL-C. In selected individuals at high cardiovascular (CV) risk, TG should be targeted, but HDL-C, Lp(a), and ratios such as LDL-C/HDL-C or apoB/apoAI are not recommended as treatment targets. Lipids should be monitored during titration to targets. Thereafter, lipids should be checked at least once a year or more frequently to improve treatment adherence if indicated. Monitoring of muscle and liver enzymes should be done before the start of treatment. In stable conditions during treatment, the focus should be on clinical symptoms that may alert muscle or liver complications. Routine measurement of CK or ALT is not necessary during treatment with statins. Springer US 2013-07-26 2013 /pmc/articles/PMC3751280/ /pubmed/23888382 http://dx.doi.org/10.1007/s11886-013-0397-8 Text en © The Author(s) 2013 https://creativecommons.org/licenses/by-nc/2.0/ Open Access This article is distributed under the terms of the Creative Commons Attribution License which permits any use, distribution, and reproduction in any medium, provided the original author(s) and the source are credited.
spellingShingle Lipid Abnormalities and Cardiovascular Prevention (G De Backer, Section Editor)
Wiklund, Olov
Pirazzi, Carlo
Romeo, Stefano
Monitoring of Lipids, Enzymes, and Creatine Kinase in Patients on Lipid-Lowering Drug Therapy
title Monitoring of Lipids, Enzymes, and Creatine Kinase in Patients on Lipid-Lowering Drug Therapy
title_full Monitoring of Lipids, Enzymes, and Creatine Kinase in Patients on Lipid-Lowering Drug Therapy
title_fullStr Monitoring of Lipids, Enzymes, and Creatine Kinase in Patients on Lipid-Lowering Drug Therapy
title_full_unstemmed Monitoring of Lipids, Enzymes, and Creatine Kinase in Patients on Lipid-Lowering Drug Therapy
title_short Monitoring of Lipids, Enzymes, and Creatine Kinase in Patients on Lipid-Lowering Drug Therapy
title_sort monitoring of lipids, enzymes, and creatine kinase in patients on lipid-lowering drug therapy
topic Lipid Abnormalities and Cardiovascular Prevention (G De Backer, Section Editor)
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3751280/
https://www.ncbi.nlm.nih.gov/pubmed/23888382
http://dx.doi.org/10.1007/s11886-013-0397-8
work_keys_str_mv AT wiklundolov monitoringoflipidsenzymesandcreatinekinaseinpatientsonlipidloweringdrugtherapy
AT pirazzicarlo monitoringoflipidsenzymesandcreatinekinaseinpatientsonlipidloweringdrugtherapy
AT romeostefano monitoringoflipidsenzymesandcreatinekinaseinpatientsonlipidloweringdrugtherapy